Abstract
Ranpirnase (ONCONASE®, a trademark of Alfacell Corporation), a cytotoxic amphibian ribonuclease, is known to be selectively tumoricidal against cancer cells. This article briefly summarizes in vitro and in vivo tumoricidal studies of ranpirnase. It proposes mechanisms of ranpirnase based on preclinical and clinical trials. Ranpirnase significantly inhibited oxygen consumption while demonstrating improvement in several tumor physiological parameters including tumor blood flow (TBF). Ranpirnase showed chemo-sensitization with various chemotherapeutic agents in vitro and in vivo. Ranpirnase significantly reduced the tumor hypertension, the major physiological barrier of therapeutic drug delivery to solid tumors. This resulted in increased tumor penetration and selectively increased TBF. This enhanced efficacy of chemotherapeutic agents including cisplatin and doxorubicin. The possible ranpirnase-related signal transduction pathways are discussed in the context of the enhanced induction of apoptosis and inhibition of protein synthesis. As a selective cancer killer ranpirnase may be a promising candidate for improving the treatment of mesothelioma and lung cancer patients.
Keywords: Ranpirnase, ONCONASE®, mesothelioma, lung cancer, apoptosis, protein inhibition, tumor hypertension, tumor blood flow
Current Cancer Therapy Reviews
Title: Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Volume: 6 Issue: 1
Author(s): Intae Lee, Daehong Kim, Jihean Lee and Kuslima Shogen
Affiliation:
Keywords: Ranpirnase, ONCONASE®, mesothelioma, lung cancer, apoptosis, protein inhibition, tumor hypertension, tumor blood flow
Abstract: Ranpirnase (ONCONASE®, a trademark of Alfacell Corporation), a cytotoxic amphibian ribonuclease, is known to be selectively tumoricidal against cancer cells. This article briefly summarizes in vitro and in vivo tumoricidal studies of ranpirnase. It proposes mechanisms of ranpirnase based on preclinical and clinical trials. Ranpirnase significantly inhibited oxygen consumption while demonstrating improvement in several tumor physiological parameters including tumor blood flow (TBF). Ranpirnase showed chemo-sensitization with various chemotherapeutic agents in vitro and in vivo. Ranpirnase significantly reduced the tumor hypertension, the major physiological barrier of therapeutic drug delivery to solid tumors. This resulted in increased tumor penetration and selectively increased TBF. This enhanced efficacy of chemotherapeutic agents including cisplatin and doxorubicin. The possible ranpirnase-related signal transduction pathways are discussed in the context of the enhanced induction of apoptosis and inhibition of protein synthesis. As a selective cancer killer ranpirnase may be a promising candidate for improving the treatment of mesothelioma and lung cancer patients.
Export Options
About this article
Cite this article as:
Lee Intae, Kim Daehong, Lee Jihean and Shogen Kuslima, Physiological and Molecular Role of Ranpirnase on Cancer Treatment, Current Cancer Therapy Reviews 2010; 6 (1) . https://dx.doi.org/10.2174/157339410790596425
DOI https://dx.doi.org/10.2174/157339410790596425 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics In Silico Transcriptomic Analysis of the Chloride Intracellular Channels (CLIC) Interactome Identifies a Molecular Panel of Seven Prognostic Markers in Patients with Pancreatic Ductal Adenocarcinoma
Current Genomics Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Cancer Gene Therapy by Adenovirus-Mediated Gene Transfer
Current Gene Therapy Acrylamide Induced Toxicity and the Propensity of Phytochemicals in Amelioration: A Review
Central Nervous System Agents in Medicinal Chemistry Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Liposomal Formulation of Monovalent Cholesteryl Cytofectins with Acyclic Head Groups and Gene Delivery: A Systematic Review
Current Pharmaceutical Biotechnology Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy